$191.31▲ 1.04 (0.55%)
Real-time prices · US Markets96% of 25 covering analysts have a positive rating.
low return on equity (-79%).
Quality
2
Health
7.7
Growth
3.6
Valuation
5.7
Sentiment
8.9
Analyst Target
$258.84
▲ +35.3% from current
Price Chart
Latest News
- Medicilon Presents Revolution Medicines with the "Excellence in Client Partnership Award"
- Novocure CEO Says RVMD’s Daraxonrasib Slowed Optune Pax Adoption – Wedbush Sees Disruption Rather Than Direct Competition
- NovoCure Sinks 5% Despite Guidance Raise as Pancreatic Cancer Launch Access Is “Significantly Limited”
Fundamentals
Trailing P/E
—
price-to-earnings
Forward P/E
-33.2×
next 12 months est.
Market Cap
$41.0B
market capitalization
Div Yield
0.00%
dividend yield
Profit Margin
0.0%
net profit margin
Gross Margin
0.0%
revenue minus COGS
ROE
-79.1%
return on equity
Beta
1.40
vs S&P 500
52-Week Range
$57 — $224
annual min — max
EPS — Estimate vs Actual
Frequently Asked Questions
What do analysts say about Revolution Medicines, Inc. right now?
Revolution Medicines, Inc.'s Q·Score is 5.2/10 (Bearish), reflecting its current fundamentals, analyst data, and valuation metrics. 96% of 25 covering analysts have a positive rating. Key area to monitor: low return on equity (-79%). This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.
What is the analyst price target for RVMD?
The consensus price target for RVMD is $258.84, based on ratings from 24 Wall Street analysts. This is 35.3% above the current price of $191.31. Price targets are forward-looking estimates and not guarantees of future performance.
Is RVMD overvalued or undervalued?
Revolution Medicines, Inc. (RVMD) scores in line with sector averages on valuation metrics. The consensus analyst price target of $258.84 is 35% above the current price.
When does Revolution Medicines, Inc. report its next earnings?
Revolution Medicines, Inc. is scheduled to report earnings in 4 days, on November 4, 2026.
What is Revolution Medicines, Inc.'s profit margin?
Revolution Medicines, Inc. has a net profit margin of 0.0%, indicating the company is currently operating at a net loss. Its gross margin stands at 0.0%, reflecting a more cost-intensive business model.
How much debt does Revolution Medicines, Inc. have?
Revolution Medicines, Inc. has a debt-to-equity ratio of 0.46×, reflecting a moderate debt level, which is manageable for most profitable companies. Its current ratio is 11.38×, indicating comfortable short-term liquidity.